A simple immunohistochemical panel comprising 2 conventional markers, Ki67 and p53, is a powerful tool for predicting patient outcome in luminal-type breast cancer-Reference-Cited by-同舟云学术

A simple immunohistochemical panel comprising 2 conventional markers, Ki67 and p53, is a powerful tool for predicting patient outcome in luminal-type breast cancer

Published:2013-02-06 Issue:1 Volume:13 Page:
ISSN:1472-6890
Container-title:BMC Clinical Pathology
language:en
Short-container-title:BMC Clin Pathol

Author:

Kobayashi Takayuki,Iwaya Keiichi,Moriya Tomoyuki,Yamasaki Tamio,Tsuda Hitoshi,Yamamoto Junji,Matsubara Osamu

Publisher

Springer Science and Business Media LLC

Subject

Histology,Pathology and Forensic Medicine

Link

http://link.springer.com/article/10.1186/1472-6890-13-5/fulltext.html

Reference38 articles.

1. Badve S, Nakshatri H: Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications. J Clin Pathol. 2009, 62 (1): 6-12. 10.1136/jcp.2008.059899.

2. Hortobagyi GN: Treatment of breast cancer. N Engl J Med. 1998, 339 (14): 974-984. 10.1056/NEJM199810013391407.

3. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998, 351 (9114): 1451-1467.

4. Mauri D, Pavlidis N, Polyzos NP, Ioannidis JP: Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst. 2006, 98 (18): 1285-1291. 10.1093/jnci/djj357.

5. Fisher B, Jeong JH, Bryant J, Anderson S, Dignam J, Fisher ER, Wolmark N: Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet. 2004, 364 (9437): 858-868. 10.1016/S0140-6736(04)16981-X.

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vitamin D3 Inhibits the Viability of Breast Cancer Cells In Vitro and Ehrlich Ascites Carcinomas in Mice by Promoting Apoptosis and Cell Cycle Arrest and by Impeding Tumor Angiogenesis;Cancers;2023-10-02

2. Clustering Molecular Subtypes in Breast Cancer, Immunohistochemical Parameters and Risk of Axillary Nodal Involvement;Journal of Personalized Medicine;2022-08-29

3. Quantification of Ki67 Change as a Valid Prognostic Indicator of Luminal B Type Breast Cancer After Neoadjuvant Therapy;Pathology and Oncology Research;2021-12-20

4. Expression of Ki67 and p53 Proteins: Breast Cancer Aggressivity Markers in Brazilian Young Patients;Journal of Adolescent and Young Adult Oncology;2021-08-01

5. Discordance in ER, PR, HER2, and Ki-67 Expression Between Primary and Recurrent/Metastatic Lesions in Patients with Primary Early Stage Breast Cancer and the Clinical Significance: Retrospective Analysis of 75 Cases;Pathology and Oncology Research;2021-04-09